Skip to main content

selcodebart

Generic: Selcodebart

selcodebart: developed by 1 company · 3 clinical trials tracked.

selcodebart evidence translation

What we can confirm

What it means

Source-backed records connect selcodebart to IRON; that link alone does not prove the drug works.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

How could selcodebart → IRON affect its developer, and what evidence supports the link?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence5 indications · 0 study sponsors

Related indications

Chronic Kidney Diseases; Inflammatory Bowel Disease (IBD); Myelofibrosis; AnemiaAnemiaChronic Kidney DiseasesMyelodysplastic SyndromesMyelofibrosis

Study sponsors

No additional listed-company sponsor is linked.

Development Pipeline (1)
CompanyPhase
Disc Medicine, Inc. (IRON)
Chronic Kidney Diseases; Inflammatory Bowel Disease (IBD); M…
Phase 2
Clinical Trials (3)

RALLY-IBD: A Phase 2 Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Efficacy of DISC-0974 in Participants With Inflammatory Bowel Disease and Anemia of Inflammation

NCT07368972·Phase 2·IRON
Recruiting

Primary endpoint: Maximal change from baseline in Hgb through Day 85

InterventionalRandomizedquadruple21 targetStarted 2026-02Completion 2027-0314 sites · United StatesDisc Medicine, Inc

A Phase 1b Multicenter, Randomized, Double-Blind, Placebo-Controlled Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DISC-0974 in Participants With Non-Dialysis Dependent Chronic Kidney Disease and Anemia

NCT05745883·Phase 1·IRON
Completed

Primary endpoint: Incidence of treatment-emergent adverse events

InterventionalRandomizedquadruple55 enrolledStarted 2023-04Completion 2026-0113 sites · United StatesDisc Medicine, Inc

RALLY-MF: A Phase 1b/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of DISC-0974 in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia

NCT05320198·Phase 1/Phase 2·IRON
Recruiting

Primary endpoint: Safety and Tolerability of DISC-0974 (Phase 1b only)

InterventionalRandomizedopen150 targetStarted 2022-06Completion 2027-0630 sites · Australia, United StatesDisc Medicine, Inc

Frequently asked questions

Who is developing selcodebart?

selcodebart is being developed by Disc Medicine, Inc..

How many clinical trials involve selcodebart?

BioSniper tracks 3 clinical trials involving selcodebart.